It has been reported that TREM2 mutations (T66M and Y38C) lead to reduced cell surface delivery and TREM2 degradation (Kleinberger et al., 2014), implicating a role for dysregulated TREM2 trafficking in AD pathogenesis. The gene discussed is TREM2; the disease is Alzheimer disease.